How Do Children and Their Caregivers Perceive the Benefits of Inhaled Asthma Therapy?

Abstract

Objective.Although well reported in adults, there is relatively little data on how children with asthma and their parents describe their attitudes to the disease, expectations of therapy, and perception of treatment benefit. We investigated this to determine if they differed from reports by adults with asthma. Methods. We recruited families with an asthmatic child (4–11 years) who had recently been prescribed a change in treatment [starting inhaled corticosteroid monotherapy (ICS) or changing from ICS to inhaled corticosteroid/long-acting β₂-agonist combination therapy (ICS/LABA)]. Semi-structured interviews were conducted with the parents and the children if aged 7–11 years. Results. We interviewed 28 parents and 13 children. All children on ICS/LABA had been changed from ICS monotherapy because of poor asthma control. Pediatric asthma had a significant impact on the whole family and both parents and children hoped the new medication would improve symptoms, increase their participation in physical activities, and decrease unscheduled visits to the GP (General Practitioner)/hospital. Positive effects of treatment change were reported by both parents and children, particularly in those changing from ICS to ICS/LABA. The most commonly reported benefits were reduced cough and wheeze, increased participation in sport or play activities, and reduced rescue medication use. These effects resulted in fewer visits to the GP/hospital and better attendance at school. Conclusions. While asthma symptoms prevent adults and children from participating in different types of activities (e.g., school, employment), children and their parents report the same benefits as previously reported in adults with asthma.

• asthma
• children
• medication
• paediatric
• interviews semi-structured

Acknowledgements

We thank Dr Clare Murray, Consultant Respiratory Pediatrician at Royal Manchester Children’s Hospital, United Kingdom, for her help in recruiting patients.

We declare receipt of the following financial support for the research and/or authorship of this article: this study was funded by an education grant (investigator led) from GlaxoSmithKline.

Declaration of Interest

We declare a potential conflict of interest as follows: Maggie Tabberer and Loretta Jacques are both employees of GlaxoSmithKline and hold stock in GlaxoSmithKline.